Suppr超能文献

尼日利亚高原州和纳萨拉瓦州年度大规模药物治疗项目中断人类盘尾丝虫病传播。

The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria.

机构信息

The Carter Center, Atlanta, Georgia.

The Carter Center Nigeria, Jos, Nigeria.

出版信息

Am J Trop Med Hyg. 2020 Mar;102(3):582-592. doi: 10.4269/ajtmh.19-0577.

Abstract

Plateau and Nasarawa states in central Nigeria were endemic for onchocerciasis. The rural populations of these two states received annual ivermectin mass drug administration (MDA) for a period of 8-26 years (1992-2017). Ivermectin combined with albendazole was given for 8-13 of these years for lymphatic filariasis (LF); the LF MDA program successfully concluded in 2012, but ivermectin MDA continued in areas known to have a baseline meso-/hyperendemic onchocerciasis. In 2017, serological and entomological assessments were undertaken to determine if MDA for onchocerciasis could be stopped in accordance with the current WHO guidelines. Surveys were conducted in 39 sites that included testing 5- to < 10-year-old resident children by using ELISA for OV16 IgG4 antibodies, and O150 pooled polymerase chain reaction (PCR) testing of s.l. vector heads. Only two of 6,262 children were OV16 positive, and none of 19,056 vector heads were positive for parasite DNA. Therefore, both states were able to meet WHO stop-MDA thresholds of an infection rate in children of < 0.1% and a rate of infective blackflies of <1/2,000, with 95% statistical confidence. Transmission of onchocerciasis was declared interrupted in Plateau and Nasarawa states by the Federal Ministry of Health, and 2.2 million ivermectin treatments/year were stopped in 2018. Post-treatment Surveillance was launched focusing on entomological monitoring on borders with neighboring onchocerciasis-endemic states. An apparent positive impact of the LF MDA program on eliminating hypo-endemic onchocerciasis was observed. This is the first stop-MDA decision for onchocerciasis in Nigeria and the largest single stop-MDA decision for onchocerciasis yet reported. This achievement, along with the process used in adapting and implementing the 2016 WHO stop-MDA guidelines, will be important as a potential model for decision makers and national onchocerciasis elimination committees in other African countries that are charged with advancing their programs.

摘要

尼日利亚中部的高原州和纳萨拉瓦州是盘尾丝虫病的地方性流行区。这两个州的农村人口在 1992 年至 2017 年期间接受了为期 8-26 年的伊维菌素大规模药物治疗(MDA)。在这 8-13 年期间,伊维菌素联合阿苯达唑用于治疗淋巴丝虫病(LF);LF MDA 项目于 2012 年成功结束,但在已知存在基线中/高度盘尾丝虫病的地区继续开展伊维菌素 MDA。2017 年,进行了血清学和昆虫学评估,以确定是否可以根据当前的世卫组织指南停止针对盘尾丝虫病的 MDA。在 39 个地点进行了调查,包括对 5-<10 岁的当地儿童进行 ELISA 检测 OV16 IgG4 抗体,以及对 s.l. 传播媒介头部进行 O150 聚合酶链反应(PCR)检测。在 6262 名儿童中只有 2 人 OV16 阳性,在 19056 个头中没有一个检测到寄生虫 DNA 阳性。因此,这两个州都能够达到世卫组织停止 MDA 的门槛,即儿童感染率<0.1%,感染性黑蝇率<1/2000,具有 95%的统计学置信度。联邦卫生部宣布终止高原州和纳萨拉瓦州的盘尾丝虫病传播,并于 2018 年停止每年 220 万次伊维菌素治疗。启动了治疗后监测,重点是与邻近盘尾丝虫病流行州接壤的昆虫监测。观察到 LF MDA 项目对消除低度流行盘尾丝虫病的明显积极影响。这是尼日利亚首次针对盘尾丝虫病停止 MDA 的决定,也是迄今为止报告的最大单一停止 MDA 的决定。这一成就以及在适应和实施 2016 年世卫组织停止 MDA 指南方面所采用的方法,将为其他负责推进其项目的非洲国家的决策者和国家盘尾丝虫病消除委员会提供重要的潜在模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/becd/7056427/79708beafc41/tpmd190577f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验